Timeless Study for Stroke
Protocol: SITE00000111
Full Title
A phase III, Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of Throbolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase
Description
This study enrolls adults who have had a recent stroke or stroke symptoms. The purpose of this study is to compare how well the study drug (tenecteplase) works for people with stroke symptoms.

You will be in this study for about 3 months and complete two 90-minute visits during that time. You will be randomized (like flipping a coin) to take either the study drug (tenecteplase) or a placebo. A placebo looks like the study drug but has no active ingredients. You will also have the current standard of care for stroke. Study takes place at Buffalo General, Gates Vascular Institute, and UBMD Neurology locations.

Technical Description

The primary analysis is to compare the efficacy of tenecteplase versus placebo in all patients at Day 90.
Compensation: No
Eligibility
-Adults ages 18+.
-Have been diagnosed with a stroke or stroke symptoms.
-Please contact the research team for other eligibility criteria.
Age Group: Adults
ClinicalTrials.gov: Open Study
Want to Learn More?
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.
Thank you for your interest. This study has restricted recruiting for participants and is not accepting inquiries at this time. If you are interested in learning more about research at UB contact ctsiresearch@buffalo.edu.